Blood tests for earlier and more accurate diagnosis of Alzheimer's disease
Tests whether blood biomarker results help memory clinics diagnose Alzheimer's disease.
Plain-language title generated from the registry record
Registry title: The BRidge Towards Implementation of Blood-based Biomarkers to Enable Early and Accurate Diagnosis of Alzheimer's Disease
Key facts
- Where
- 's-Hertogenbosch, Almere Stad, Amsterdam, Haarlem, Hilversum, Leeuwarden, Purmerend, and Tilburg, NetherlandsSee the 8 sites
Where in Netherlands
- Jeroen Bosch Ziekenhuis's-Hertogenbosch, NetherlandsTaking people
- FlevoziekenhuisAlmere Stad, NetherlandsTaking people
- Amsterdam UMCAmsterdam, NetherlandsTaking people
- Spaarne GasthuisHaarlem, NetherlandsTaking people
- Tergooi MCHilversum, NetherlandsTaking people
- Frisius MCLeeuwarden, NetherlandsTaking people
- Dijklander ZiekenhuisPurmerend, NetherlandsTaking people
- Elisabeth-Tweesteden ZiekenhuisTilburg, NetherlandsNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Alzheimercentrum Amsterdam
- Trial code
- NCT07680335
- Record updated
- 2 July 2026
- Original description
Cognitive disorders have a broad differential diagnosis, and a precise, timely diagnosis is essential for personalized treatment and care. Currently, dementia diagnoses are often not further specified according to the underlying pathology and are frequently delayed by several years. However, with the upcoming disease-modifying treatments (DMTs) for AD, an accurate, pathology-driven (i.e., etiological) diagnosis will become necessary.Read full original descriptionShow less
The BRidge Towards Implementation of Blood-based Biomarkers to Enable Early and Accurate Diagnosis of Alzheimer's Disease (BRIDGE-AD2)
Cognitive disorders have a broad differential diagnosis, and a precise, timely diagnosis is essential for personalized treatment and care. Currently, dementia diagnoses are often not further specified according to the underlying pathology and are frequently delayed by several years. However, with the upcoming disease-modifying treatments (DMTs) for AD, an accurate, pathology-driven (i.e., etiological) diagnosis will become necessary.
Blood-based biomarkers (BBMs) are promising tools for detecting Alzheimer's disease (AD), with current research showing high concordance with cerebrospinal fluid (CSF) biomarkers and amyloid PET imaging. However, it remains unclear how physicians would value the availability of BBMs for AD in routine clinical practice. The investigators hypothesize that BBMs will benefit both patients and physicians in the diagnostic process within a memory clinic setting.
This study aims to investigate clinical impact and diagnostic utility of blood-based biomarkers for AD in the diagnostic process of a memory clinic. The main objectives are to investigate change in diagnosis, diagnostic certainty and patient management, due to BBM results.
Inclusion: Patient presents in memory clinic with cognitive complaints; The physician is concerned about underlying AD as etiology of the complaints; Adequate fluency in Dutch to understand informed consent procedure.
Exclusion: Previous biomarker-confirmed diagnosis of AD; Alcohol or drug abuse to such an extent that treatment would be advisable; Age under 55; Patient is incapacitated, and is not able to judge consequences of participation.